JP2021527694A5 - - Google Patents

Info

Publication number
JP2021527694A5
JP2021527694A5 JP2020570967A JP2020570967A JP2021527694A5 JP 2021527694 A5 JP2021527694 A5 JP 2021527694A5 JP 2020570967 A JP2020570967 A JP 2020570967A JP 2020570967 A JP2020570967 A JP 2020570967A JP 2021527694 A5 JP2021527694 A5 JP 2021527694A5
Authority
JP
Japan
Prior art keywords
virus
inhibitor
gene encoding
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527694A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2019/051769 external-priority patent/WO2019243847A1/en
Publication of JP2021527694A publication Critical patent/JP2021527694A/ja
Publication of JP2021527694A5 publication Critical patent/JP2021527694A5/ja
Priority to JP2024076002A priority Critical patent/JP2024105452A/ja
Pending legal-status Critical Current

Links

JP2020570967A 2018-06-21 2019-06-21 腫瘍溶解性ウイルスを用いた処置 Pending JP2021527694A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076002A JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862687931P 2018-06-21 2018-06-21
US201862687920P 2018-06-21 2018-06-21
US201862687881P 2018-06-21 2018-06-21
US201862687910P 2018-06-21 2018-06-21
US62/687,931 2018-06-21
US62/687,920 2018-06-21
US62/687,910 2018-06-21
US62/687,881 2018-06-21
PCT/GB2019/051769 WO2019243847A1 (en) 2018-06-21 2019-06-21 Treatment using oncolytic virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076002A Division JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Publications (2)

Publication Number Publication Date
JP2021527694A JP2021527694A (ja) 2021-10-14
JP2021527694A5 true JP2021527694A5 (cg-RX-API-DMAC7.html) 2022-06-24

Family

ID=67262783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570967A Pending JP2021527694A (ja) 2018-06-21 2019-06-21 腫瘍溶解性ウイルスを用いた処置
JP2024076002A Pending JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076002A Pending JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Country Status (6)

Country Link
US (1) US12685767B2 (cg-RX-API-DMAC7.html)
EP (1) EP3810191A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021527694A (cg-RX-API-DMAC7.html)
CN (1) CN112601547A (cg-RX-API-DMAC7.html)
CA (1) CA3103371A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019243847A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400291B2 (en) 2016-01-08 2024-02-28 Replimune Limited Engineered virus
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
US11951141B2 (en) * 2019-11-06 2024-04-09 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
WO2021205364A1 (en) * 2020-04-07 2021-10-14 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered oncolytic adenovirus
KR20230012484A (ko) * 2020-05-20 2023-01-26 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
WO2022235810A1 (en) * 2021-05-04 2022-11-10 Tukey David A biological entity for treating brain cancer
CN113244411B (zh) * 2021-06-25 2021-09-17 诺赛联合(北京)生物医学科技有限公司 一种基因修饰的溶瘤病毒诱导ctl细胞方法及其在肿瘤治疗的用途
CN113699122B (zh) * 2021-08-31 2023-10-20 中国科学院大学宁波华美医院 一种多基因融合溶瘤腺病毒及其构建方法和应用
CN114350709A (zh) * 2021-09-18 2022-04-15 梁亚龙 一种经修饰的溶瘤性腺病毒载体
CN116836283B (zh) * 2022-05-17 2024-05-07 苏州万灏生物科技有限公司 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
WO2023226942A1 (zh) * 2022-05-23 2023-11-30 上海药明康德新药开发有限公司 一种编码免疫刺激因子和抗免疫检查点抗体的重组hsv-1载体
WO2024082263A1 (zh) * 2022-10-21 2024-04-25 上海鑫湾生物科技有限公司 一种响应缺氧环境控制病毒复制的系统及其用途
CN115976109B (zh) * 2022-11-07 2025-06-27 武汉大学 一种靶向降解gbp蛋白的hsv-1溶瘤病毒及其制备与应用
CN116555191B (zh) * 2023-05-26 2024-09-17 东北农业大学 编码白细胞介素24和粒细胞-巨噬细胞集落刺激因子的新城疫病毒在肿瘤治疗中的应用
CN117797263B (zh) * 2023-11-29 2024-06-18 华南农业大学 一种药物组合物、药物和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
CA2132976C (en) 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
EP0862445B2 (en) 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2502078A1 (en) 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
ES2704632T3 (es) * 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AU2013296919A1 (en) 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
EA201590451A1 (ru) 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
PL3041490T3 (pl) 2013-09-03 2019-05-31 Medimmune Ltd Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
US10933106B2 (en) 2014-02-25 2021-03-02 Deutsches Krebsforschungszentrum RNA viruses for immunovirotherapy
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10525557B2 (en) 2015-01-23 2020-01-07 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
EP3400291B2 (en) * 2016-01-08 2024-02-28 Replimune Limited Engineered virus
KR102323872B1 (ko) 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
CN113454231A (zh) 2018-12-21 2021-09-28 渥太华医院研究所 修饰的正痘病毒载体

Similar Documents

Publication Publication Date Title
US12458696B2 (en) Modified oncolytic virus
JP7146852B2 (ja) 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
JP2019500909A5 (cg-RX-API-DMAC7.html)
JP2020503871A5 (cg-RX-API-DMAC7.html)
JP2024095709A5 (cg-RX-API-DMAC7.html)
JP2019501670A5 (cg-RX-API-DMAC7.html)
JP2019501671A5 (cg-RX-API-DMAC7.html)
JP2021518408A5 (cg-RX-API-DMAC7.html)
HK40045432A (en) Modified oncolytic virus
HK1257224B (en) Modified oncolytic virus
HK1257480B (en) Engineered virus